[Detection of disseminated carcinoma cells in bone marrow and peripheral blood in primary @entity0 with @entity138 /PCR of XXXX ( @entity4293 )].

@entity1 @entity0 @entity4293 @entity5 @entity138 @entity3
The analysis of tissue specific gene expression by reverse transcription based @entity138 /PCR methods is currently evaluated as a method for the detection of @entity5 cell dissemination in @entity1 with @entity5 . @entity0 tissues express @entity4293 and the level of @entity4293 expression in the primary @entity5 correlates with the incidence of @entity3 in the bone. We applied a @entity138 /PCR assay of @entity4293 to detect @entity5 cells in the mononuclear cell fraction of peripheral blood (pb) and bone marrow (bm) of @entity1 with newly diagnosed @entity0 . @entity4293 positivity was found in 18/67 pb and 20/71 bm samples. In a median follow up of 23 months there were 7 metastatic relapses (4 osseous, 2 hepatic, 1 pulmonary) and 9 local relapses in @entity1 with primary lymph node positive @entity0 . The hepatic and pulmonary relapses had been both @entity4293 -PCR negative in pb and in bm. Of the 4 @entity1 with metastatic relapses to the bone the samples of bm had been initially negative in all cases, the pb had been positive in 2 cases. Of the 9 @entity1 with local recurrences the pb alone had been positive in 4 @entity1 , 5 @entity1 had been negative in both the pb and the bm. During the period of observation there was no local and metastatic relapse detectable in the group of @entity1 with primary lymph node negative @entity0 . In summary the increased risk for local or systemic relapse would have been predictable by @entity138 /PCR of @entity4293 alone in pb in 4 of the 9 local and in 2 of the 7 early metastatic relapses. Further follow-up of the @entity1 cohort analysed is needed to assess the value of the @entity138 /PCR of @entity4293 as a prognostic and predictive marker in @entity1 with @entity0 .
